|drug3266||Tafenoquine Oral Tablet Wiki||1.00|
There is one clinical trial.
We hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
Description: Change is clinical status as captured by 7-point ordinal scale to include Death Hospitalized, requiring mechanical ventilation or ECMO Hospitalized, requiring non-invasive ventilation or high flow oxygen Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen--requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen-not requiring ongoing medical care (COVID-19 related or otherwise). Not HospitalizedMeasure: Change is clinical status Time: Time of plasma infusion (day 0) compared to day 7
Description: Presence of any adverse events related to plasma infusionMeasure: Transfusion related events Time: Within 6 hours of infusion
Description: Change in 7-point ordinal scale score from time of plasma infusion (day 0-prior to first infusion) to days 14, 21, and 28Measure: Change is clinical status Time: Time of plasma infusion (day 0 prior to first infusion) to days 14, 21, and 28
Description: Assess change in Sequential Organ Failure Assessment (SOFA) scoreMeasure: SOFA score at days 0, 7, 14, 21, 28 Time: Days 0, 7, 14, 21, 28
Description: Total duration of hospitalMeasure: Length of Hospital Stay Time: Days 7, 14, 21, 28
Description: Time to discontinuation of supplemental oxygenMeasure: Supplemental oxygen Time: Days 7, 14, 21, 28
Description: Need for mechanical ventilation (for those patients not on the ventilator)Measure: Mechanical Ventilation Time: Days 7, 14, 21, 28
Description: Time to liberation from mechanical ventilation (for patients on a ventilator)Measure: Change in mechanical ventilation status Time: Days 7, 14, 21, 28
Description: All-cause MortalityMeasure: Mortality Time: Day 28
Description: Change in standard of care inflammatory markers (ferritin, LDH, CRP, D-dimer)Measure: Change in inflammatory markers Time: Day 0 to days 7, 14, 21, 28
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports